A randomised, double‐blinded trial to assess the effect of oclacitinib and prednisolone on intradermal allergen and prick tests in dogs with atopic dermatitis

Abstract

AbstractBackgroundIntradermal (IDT) and prick (PT) tests are used to select allergens for allergen‐specific immunotherapy in dogs with atopic dermatitis (cAD). However, the use of antipruritic drugs before performing these tests may influence the results.ObjectiveTo evaluate the influence of the drugs oclacitinib and prednisolone on the immediate‐phase reactions of IDT and PT.AnimalsThirty client‐owned dogs with cAD with positive reactions to at least one allergen extract on IDT or PT.Materials and MethodsDogs were randomly assigned to receive oclacitinib 0.4–0.58 mg/kg per os, every 12 h (n = 14), or prednisolone 0.37–0.65 mg/kg p.o., every 12 h (n = 16) for 14 days. IDT and PT were performed on Day (D)0 before treatment and on D14.ResultsAt D14 there was no significant reduction in the means of the orthogonal diameters of the positive immediate‐phase reactions of the IDT (p = 0.064) in the oclacitinib group; however, in the PT, the diameter of the positive reactions reduced significantly (p = 0.048). In both tests, there was no significant reduction in the total number of positive reactions (IDT, p > 0.999; PT, p = 0.735). In the prednisolone group, the means of the orthogonal diameters of positive immediate‐phase reactions were significantly reduced in both tests (IDT, p = 0.001; PT, p ≤ 0.001) and there also was a reduction in the total number of positive reactions (IDT, p = 0.022; PT, p = 0.001).Conclusions and Clinical RelevanceThe use of oclacitinib 0.4–0.58 mg/kg twice daily for 14 days does not interfere with IDT results in dogs with cAD. However, oclacitinib may reduce PT reactivity. The use of prednisolone 0.37–0.65 mg/kg twice daily results in a reduction in both IDT and PT results.